Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near

Résumé détaillé

Denali Therapeutics (NASDAQ:DNLI) is targeting all eligible U.S. patients for its Hunter disease treatment AVLAYAH, while preparing data updates across a pipeline that includes treatments for Sanfilippo syndrome, Pompe disease and Alzheimer’s disease. Chief Scientific Officer Joe Lewcock said AVLAY